Compare INSP & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSP | TNDM |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2018 | 2013 |
| Metric | INSP | TNDM |
|---|---|---|
| Price | $62.55 | $19.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 19 |
| Target Price | ★ $94.00 | $28.00 |
| AVG Volume (30 Days) | 399.3K | ★ 1.4M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 179.43 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $82,050,000.00 | ★ $1,014,736,000.00 |
| Revenue This Year | $8.02 | $8.11 |
| Revenue Next Year | $8.11 | $11.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 62.18 | 7.93 |
| 52 Week Low | $38.91 | $11.46 |
| 52 Week High | $147.03 | $29.65 |
| Indicator | INSP | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 59.82 | 43.29 |
| Support Level | $56.50 | $19.70 |
| Resistance Level | $66.21 | $20.79 |
| Average True Range (ATR) | 2.64 | 1.06 |
| MACD | -0.21 | -0.46 |
| Stochastic Oscillator | 71.00 | 11.43 |
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.